Gadolinium use in patients with kidney disease: A cause for concern

Seminars in Dialysis

Volumn 20, Issue 3, 2007, Pages 179-185

  Perazella, Mark A ^a   Rodby, Roger A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE;

CHEMICALLY INDUCED DISORDER; FIBROSIS; HUMAN; KIDNEY; KIDNEY DISEASE; METABOLISM; REVIEW;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM DTPA; HUMANS; KIDNEY; KIDNEY DISEASES;

EID: 34250025385     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2007.00269.x     Document Type: Review

References (31)

1. Rodby RA : Dialyzing radiographic contrast media: is there a role? Sem Dial 20 : 19 23, 2007
2. Cruz DN, Perazella MA, Bellomo R, Corradi V, de Cal M, Kuang D, Ocampo C, Nalesso F, Ronco C : Extracorporial blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis 48 : 361 371, 2006
3. Grobner T : Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21 : 1104 1108, 2006
4. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS : Nephrogenic systemic fibrosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 : 2359 2362, 2006
5. Bellin MF : MR contrast agents, the old and the new. Eur J Radiol 60 : 314 323, 2006
6. Lorusso V, Pascolo L, Fernetti C, Anelli PL, Uggeri F, Tiribelli C : Magnetic resonance contrast agents: from the bench to the patient. Curr Pharm Design 11 : 4079 4098, 2005
7. Runge VM : Safety of magnetic resonance contrast media. Top Magn Reson Imaging 12 : 309 314, 2001
8. Shamsi K, Yucel EK, Chamberlin P : A Summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: phase II and phase III clinical trials data. Invest Radiol 41 : 822 830, 2006
9. Swan SK, Lambrecht LJ, Townsend R, Davies BE, McCloud S, Parker JR, Bensel K, LaFrance ND : Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 34 : 443 455, 1999
10. Reinton V, Berg KJ, Svaland MG, Andrew E, Normann PJ, Rootwelt K : Pharmacokinetics of gadodiamide injection in patients with moderately impaired renal function. Acta Radiol 1 : 56 61, 1994
11. Schuhmann-Giampieri G, Krestin G : Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 11 : 975 979, 1991
12. Joffe P, Thomsen HS, Meusel M : Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acta Radiol 5 : 491 502, 1998
13. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y : Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 24 : 445 451, 2006
14. Okada S, Katagirir K, Kumazaki T, Yokoyama H : Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 42 : 339 341, 2001
15. Niendorf HP, Alhassan A, Haustein J, Clauss W, Cornelius I : Safety and risk of gadolinium-DTPA: extended clinical experience after more than 5,000,000 applications. Adv MRI Contrast 2 : 12 19, 1993
16. Bellin MF, Deray G, Assogba U, Auberton E, Ghary F, Dion-Voirin E, Jacobs C, Grellet J : Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure. Magn Reson Imaging 10 : 115 118, 1992
17. Prince MR, Arnoldus C, Friscoli JK : Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 6 : 162 166, 1996
18. Reiger J, Sitter T, Toepfer M, Linsenmaier U, Pfeofer KJ, Schiffl H : Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 17 : 824 828, 2002
19. Sam AD, Morasch MD, Collins J, Song G, Chen R, Pereles FS : Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 38 : 313 318, 2003
20. Erley CM, Bader BD, Berger ED : Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotemic patients. Nephrol Dial Transplant 19 : 2526 2531, 2004
21. Ergun I, Keven K, Uruc I, Ekmekci Y, Canbakan B, Erden I, Karatan O : The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 21 : 697 700, 2006
22. Briguori C, Colombo A, Airoldi F, Melzi G, Michev I, Carlino M, Montorfano M, Chieffo A, Bellanca R, Ricciardelli B : Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Cath Cardiovasc Intervent 67 : 175 180, 2006
23. Galan A, Cowper SE, Bucala R : Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 18 : 614 617, 2006
24. Cowper SE : Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. 2001-2006. Available at: http://www.icnfdr.org (accessed on December 12, 2006).
25. Thomsen HS, Morcos SK, Dawson P : Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis. Clin Radiol 61 : 905 906, 2006
26. Thomsen HS : Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 14 : 2619 2621, 2006
27. High WA, Ayers RA, Chandler J, Zito G, Cowper SE : Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 1 : 21 26, 2007
28. Boyd AS, Zic JA, Abraham JL : Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 1 : 27 30, 2007
29. Public Health Advisory: Gadolinium-Containing Contrast Agents for Magnetic Resonance Imaging (MRI). 2006, http://www.fda.gov/cder/drug/advisory/ gadolinium_agents.htm
30. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA : Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. Amer J Roent 188 (2) : 586 592, 2007
31. Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE : Nephrogenic systemic fibrosis: A review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 42 : 139 145, 2007